AEZS is a good if not one of the best Biotech companies out right now!
AEZS has over $25M in cash (which works out to 81 cents per share), with no debt.
Meanwhile, revenue growth year over year is 302%. Again, keep in mind that the way the books are accounted, as well as incoming royalty payments, make this a VERY misleading number. Revenues of $63.4M over the last 12 months work out to $2.70 per share.